Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia × Anti-Bacterial Agents × Clear all
NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡